Trial Profile
A phase 2 double-blind dose escalation study of KRN5500 for neuropathic pain in patients with cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jun 2012
Price :
$35
*
At a glance
- Drugs KRN 5500 (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- 09 May 2012 Results published in a DARA BioSciences media release
- 16 Aug 2011 Results accepted for publication by a peer-reviewed medical journal, according to a DARA BioSciences media release.
- 01 Feb 2011 Results from analyses of this study exploring placebo response will be presented at the International Conference on Accelerating the Development of Enhanced Pain Treatments (ADEPT) to be held in March 2011, as reported in a DARA Biosciences media release.